Citations

Showing 10 of 108081 citations.

Methadone-Induced Neurotoxicity in Advanced Cancer: A Case Report
Hoff, A.M., Hartwig, Kristopher N., Hoff, Ann M, Rosielle, Drew A.

Mayo Clinic

Journal of Palliative Medicine | May 10, 2017 | Volume: 20 | Issue: 9 | Pages: 1042-1044

10.1089/jpm.2016.0502 | PMID 28488910 Get It

Abstract Methadone use as a second-line agent for severe cancer-related pain is increasing in the field of hospice and palliative care. It has a number of qualities that make its use favorable, including lack of known active metabolites and presumed relative safety from adverse effects such as opioid-induced neurotoxicity (OIN). This article describes a case of a patient undergoing treatment of severe cancer-related pain who developed OIN in the setting of oral methadone use. As the use of methadone increases, more research into its pharmacologic and pharmacokinetic properties will be necessary.
Editorial Comment on “Distinguishing Failure to Cure From Complication After Penile Prosthesis Implantation”
Trost, Landon

Mayo Clinic

The Journal of Sexual Medicine | May 10, 2017 | Volume: 14 | Issue: 5 | Pages: 738-739

10.1016/j.jsxm.2017.02.017 | PMID 28499522 Get It

Immune modulator therapy for microscopic colitis in a case series of 73 patients
Cotter, Thomas G. , Kamboj, Amrit K. , Hicks, Stephen B., Tremaine, William J., Loftus, Edward V. , Pardi, Darrell S. , Cotter, T G , Loftus, Edward V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | May 10, 2017 | Volume: 46 | Issue: 2 | Pages: 169-174

10.1111/apt.14133 | PMID 28488312 Get It

SummaryBackgroundMicroscopic colitis (MC) is a common cause of chronic diarrhoea. Various treatment options have been described, but there are limited data describing outcomes of corticosteroid‐sparing treatments.AimTo evaluate the outcomes of patients with active MC treated with immune modulators.MethodsAll patients seen at Mayo Clinic, Rochester between January 1, 1997 and November 30, 2016 with a histological diagnosis of MC were identified. Patients treated with an immune modulator of interest were selected and clinical outcomes recorded.ResultsSeventy‐three MC patients (50 collagenous colitis and 23 lymphocytic colitis) with a median disease duration of 24 months (range, 7‐60) were included. The indications for treatment were budesonide‐refractoriness in 66%, budesonide dependence in 29%, and budesonide intolerance in 5%. Median age was 51.8 years (range, 43.4‐63.1) and 61 (84%) were female. Thiopurines were used in 49 patients (67%) for a median of 4 months (range, 1.5‐15). Complete and partial response occurred in 43% and 22% respectively. Adverse effects resulting in therapy cessation occurred in 17 patients (35%). Twelve patients (16%) were treated with methotrexate for a median of 14 months (3‐18.8). Complete and partial response occurred in 58% and 17%, respectively. Anti‐TNF therapy was used in 10 patients (14%) for a median of 4 months (range, 2.3‐5.5). Complete response occurred in four patients and partial response in four patients.ConclusionsThe majority of patients with active MC responded to thiopurines, methotrexate, or anti‐TNF therapy. Larger controlled studies are required to confirm the efficacy and safety of these medications in MC.
Acute pressure changes in the brain are correlated with MR elastography stiffness measurements: initial feasibility in an in vivo large animal model
Arani, Arvin , Min, Hoon‐Ki , Fattahi, Nikoo , Wetjen, Nicholas M. , Trzasko, Joshua D. , Jack, Clifford R. , Lee, Kendall H. , Min, Hoon-Ki Paul , Manduca, Armando , Ehman, Richard L. , Huston, John , Jack, Clifford R , Arani, Arvin

Mayo Clinic

Magnetic Resonance in Medicine | May 10, 2017 | Volume: 79 | Issue: 2 | Pages: 1043-1051

10.1002/mrm.26738 | PMID 28488326 Get It

PurposeThe homeostasis of intracranial pressure (ICP) is of paramount importance for maintaining normal brain function. A noninvasive technique capable of making direct measurements of ICP currently does not exist. MR elastography (MRE) is capable of noninvasively measuring brain tissue stiffness in vivo, and may act as a surrogate to measure ICP. The objective of this study was to investigate the impact of changing ICP on brain stiffness using MRE in a swine model.MethodsBaseline MRE measurements were obtained, and then catheters were surgically placed into the left and right lateral ventricles of three animals. ICP was systematically increased over the range of 0 to 55 millimeters mercury (mmHg), and stiffness measurements were made using brain MRE at vibration frequencies of 60 hertz (Hz), 90 Hz, 120 Hz, and 150 Hz.ResultsA significant linear correlation between stiffness and ICP in the cross‐subject comparison was observed for all tested vibrational frequencies (P ≤ 0.01). The 120 Hz (0.030 ± 0.004 kilopascal (kPa)/mmHg, P < 0.0001) and 150 Hz (0.031 ± 0.008 kPa/mmHg, P = 0.01) vibrational frequencies had nearly identical slopes, which were approximately two‐ to three‐fold higher than the 90 Hz (0.017 ± 0.002 kPa/mmHg, P < 0.0001) and 60 Hz (0.009 ± 0.002 kPa/mmHg, P = 0.001) slopes, respectively.ConclusionIn this study, MRE demonstrated the potential for noninvasive measurement of changes in ICP. Magn Reson Med 79:1043–1051, 2018. © 2017 The Authors Magnetic Resonance in Medicine published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics
Κατσάνος, Κωνσταντίνος, Papadakis, Konstantinos A.

Mayo Clinic

Gut and Liver | May 10, 2017 | Volume: 11 | Issue: 4 | Pages: 455-463

10.5009/gnl16308 | PMID 28486793 Get It

Management of Panfacial Fracture
Lettieri, Salvatore C. , Ali, Kausar

Mayo Clinic

Seminars in Plastic Surgery | May 9, 2017 | Volume: 31 | Issue: 02 | Pages: 108-117

10.1055/s-0037-1601579 | PMID 28496391 Get It

A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy
Eugene, Andy R., Masiak, Jolanta , Eugene, Andy R.

Mayo Clinic

Nordic Journal of Psychiatry | May 9, 2017 | Volume: 71 | Issue: 6 | Pages: 417-424

10.1080/08039488.2017.1314011 | PMID 28486094 Get It

EGFR Signals through a DOCK180-MLK3 Axis to Drive Glioblastoma Cell Invasion
Misek, Sean A. , Schroeder, Laura E., Rattanasinchai, Chotirat, Sample, Ashley, Gallo, Kathleen A. , Chen, Jian , Sarkaria, Jann N.

Mayo Clinic

Molecular Cancer Research | May 9, 2017 | Volume: 15 | Issue: 8 | Pages: 1085-1095

10.1158/1541-7786.mcr-16-0318 | PMID 28487380 Get It

Abstract A hallmark of glioblastoma (GBM) tumors is their highly invasive behavior. Tumor dissemination into surrounding brain tissue is responsible for incomplete surgical resection, and subsequent tumor recurrence. Identification of targets that control GBM cell dissemination is critical for developing effective therapies to treat GBM. A majority of GBM tumors have dysregulated EGFR signaling, due most frequently to EGFR amplification or the presence of a constitutively active EGFRvIII mutant. Mixed lineage kinase 3 (MLK3) is a mitogen-activated protein kinase kinase kinase (MAP3K) that can activate multiple MAPK pathways. In this study, evidence is provided that MLK3 is essential for GBM cell migration and invasion, and that an MLK inhibitor blocks EGF-induced migration and invasion. MLK3 silencing or MLK inhibition blocks EGF-induced JNK activation, suggesting that MLK3-JNK signaling promotes invasion of GBM cells. Mechanistically, it is demonstrated that DOCK180, a RAC1 guanine nucleotide exchange factor (GEF) overexpressed in invasive GBM cells, activates the MLK3-JNK signaling axis in a RAC1-dependent manner. In summary, this investigation identifies an EGFR–DOCK180–RAC1–MLK3–JNK signaling axis that drives glioblastoma cell migration and dissemination. Implications: On the basis of these findings, MLK3 emerges as a potential therapeutic target for the treatment of glioblastoma. Mol Cancer Res; 15(8); 1085–95. ©2017 AACR.
Objectivity in subjectivity: do students’ self and peer assessments correlate with examiners’ subjective and objective assessment in clinical skills? A prospective study
Inayah, A’man Talal, Anwer, Lucman A. , Shareef, Mohammad Abrar , Nurhussen, Akram, Alkabbani, Haifa Mazen, Alzahrani, Alhanouf A, Obad, Adam S, Afsar, Nasir Ali , ALKABBANI, HAIFAA M., Zafar, Muhammad

Mayo Clinic

BMJ Open | May 9, 2017 | Volume: 7 | Issue: 5 | Pages: e012289

10.1136/bmjopen-2016-012289 | PMID 28487454 Get It

Objectives The qualitative subjective assessment has been exercised either by self-reflection (self-assessment (SA)) or by an observer (peer assessment (PA)) and is considered to play an important role in students’ development. The objectivity of PA and SA by students as well as those by faculty examiners has remained debated. This matters most when it comes to a high-stakes examination. We explored the degree of objectivity in PA, SA, as well as the global rating by examiners being Examiners’ Subjective Assessment (ESA) compared with Objective Structured Clinical Examinations (OSCE). Design Prospective cohort study. Setting Undergraduate medical students at Alfaisal University, Riyadh. Participants All second-year medical students (n=164) of genders, taking a course to learn clinical history taking and general physical examination. Main outcome measures A Likert scale questionnaire was distributed among the participants during selected clinical skills sessions. Each student was evaluated randomly by peers (PA) as well as by himself/herself (SA). Two OSCEs were conducted where students were assessed by an examiner objectively as well as subjectively (ESA) for a global rating of confidence and well-preparedness. OSCE-1 had fewer topics and stations, whereas OSCE-2 was terminal and full scale. Results OSCE-1 (B=0.10) and ESA (B=8.16) predicted OSCE-2 scores. ‘No nervousness’ in PA (r=0.185, p=0.018) and ‘confidence’ in SA (r=0.207, p=0.008) correlated with ‘confidence’ in ESA. In ‘well-preparedness’, SA correlated with ESA (r=0.234, p=0.003). Conclusions OSCE-1 and ESA predicted students’ performance in the OSCE-2, a high-stakes evaluation, indicating practical ‘objectivity’ in ESA, whereas SA and PA had minimal predictive role. Certain components of SA and PA correlated with ESA, suggesting partial objectivity given the limited objectiveness of ESA. Such difference in ‘qualitative’ objectivity probably reflects experience. Thus, subjective assessment can be used with some degree of objectivity for continuous assessment.
Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
Jones, Jeremy , Renfro, Lindsay A. , Al‐Shamsi, Humaid O. , Schrock, Alexa B. , Rankin, Andrew, Zhang, Ben Y., Kasi, Pashtoon Murtaza , Voss, Jesse S. , Leal, Alexis D. , Ali, Siraj M. , Kipp, Benjamin R. , Kopetz, Scott , Wolff, Robert A. , Jones, Jeremy C., Kasi, Pashtoon M, Sun, James, Ross, Jeffrey , Hubbard, Joleen M. , McWilliams, Robert R. , Jones, Jeremy C , Kasi, Pashtoon Murtaza , Sun, James X. , Ross, Jeffrey S , Grothey, Axel , Kopetz, Scott , Al-Shamsi, Humaid O

Mayo Clinic

Journal of Clinical Oncology | May 9, 2017 | Volume: 35 | Issue: 23 | Pages: 2624-2630

10.1200/jco.2016.71.4394 | PMID 28486044 Get It

Purpose Molecular diagnostic testing has become an integral part of the evaluation of patients with metastatic colorectal cancer (CRC). Expanded mutational testing, such as next-generation sequencing (NGS), often identifies mutations with unclear clinical or prognostic implications. One such example is BRAF mutations that occur outside of codon 600 (non-V600 BRAF mutations). Methods We conducted this multicenter, retrospective cohort study to characterize the clinical, pathologic, and survival implications of non-V600 BRAF mutations in metastatic CRC. We pooled patients in whom non-V600 BRAF mutations were identified from NGS databases at three large molecular genetics reference laboratories. Results A total of 9,643 patients with metastatic CRC underwent NGS testing. We identified 208 patients with non-V600 BRAF mutations, which occurred in 2.2% of all patients tested and accounted for 22% of all BRAF mutations identified. Cancers with non-V600 BRAF mutations, compared with cancers with V600E BRAF (V600E BRAF) mutations, were found in patients who were significantly younger (58 v 68 years, respectively), fewer female patients (46% v 65%, respectively), and patients who had fewer high-grade tumors (13% v 64%, respectively) or right-sided primary tumors (36% v 81%, respectively). Median overall survival was significantly longer in patients with non-V600 BRAF-mutant metastatic CRC compared with those with both V600E BRAF-mutant and wild-type BRAF metastatic CRC (60.7 v 11.4 v 43.0 months, respectively; P < .001). In multivariable analysis, non-V600 BRAF mutation was independently associated with improved overall survival (hazard ratio, 0.18; P < .001). Conclusion Non-V600 BRAF mutations occur in approximately 2.2% of patients with metastatic CRC and define a clinically distinct subtype of CRC with an excellent prognosis.